Targeting human prostaglandin reductase 1 with Licochalcone A: Insights from molecular dynamics and covalent docking

Sara Abigail Ramírez-Cortés1, Adrián Durán-Vargas1, Jesús Antonio Rauda-Ceja1

  • 1Universidad Nacional Autónoma de México, Instituto de Química, Ciudad Universitaria, Ciudad de Mexico, 04510, Mexico.

Biophysical Chemistry
|February 18, 2025
PubMed

Insights

Licochalcone A inhibits Prostaglandin reductase 1 (PTGR1), an enzyme linked to cancer progression. Molecular simulations reveal its binding mechanism, identifying PTGR1

Area of Science:

  • Biochemistry
  • Enzymology
  • Molecular Biology

Background:

  • Prostaglandin reductase 1 (PTGR1) is an NADPH-dependent enzyme crucial for eicosanoid metabolism.
  • Elevated PTGR1 expression in tumors correlates with poor prognosis, as it protects cancer cells from reactive oxygen species.

Purpose of the Study:

  • To investigate the inhibitory potential of licochalcone A, a natural flavonoid, on human PTGR1.
  • To elucidate the structural and dynamic mechanisms underlying PTGR1 inhibition by licochalcone A.

Main Methods:

  • Molecular dynamics simulations to map PTGR1's conformational landscape.
  • Covalent and solvent site-guided molecular docking to determine licochalcone A binding modes.
  • Sequence analysis of PTGR1 orthologs and structural comparison with other NADPH-binding proteins.

Main Results:

  • PTGR1 exhibits a low-energy conformational transition between open and closed states, regulated by intersubunit interactions and NADPH binding.
  • Licochalcone A demonstrates a highly favorable covalent binding pose at the NADPH-binding site, consistent with noncovalent docking predictions.
  • The coenzyme-binding site shows stereochemical complementarity to licochalcone A.

Conclusions:

  • Licochalcone A is a promising lead compound for developing PTGR1-specific inhibitors.
  • The coenzyme-binding site of PTGR1 represents a viable target for therapeutic intervention.
  • Understanding PTGR1's conformational dynamics is key to designing effective inhibitors.